SVB Leerink Maintains Market Perform on Editas Medicine, Lowers Price Target to $12
SVB Leerink analyst Mani Foroohar maintains Editas Medicine (NASDAQ:EDIT) with a Market Perform and lowers the price target from $14 to $12.
Editas Medicine Q3 EPS $(0.81) Beats $(0.86) Estimate. The Company Reported Collaboration Revenue Of $42K
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.86) by 5.81 percent. This is a 42.11 percent decrease over losses of $(0.57) per share from
Traders Circulate ‘Struggling Editas Shops Preclinical Cancer Pipeline During Its Big Makeover’ – Endpoints News
EXCLUSIVE: Struggling Editas shops preclinical cancer pipeline during its big makeover – Endpoints News (endpts.com)
Barclays Maintains Equal-Weight on Editas Medicine, Raises Price Target to $17
Barclays analyst Gena Wang maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and raises the price target from $16 to $17.